Weight loss injections have become an important medical treatment option for eligible people living with obesity or overweight with associated health conditions.
Medicines such as Mounjaro (tirzepatide) and Wegovy (semaglutide) have increased interest in medically supervised weight management across India.
However, one of the most common questions patients ask before beginning treatment is:
“How much will weight loss injections cost in India in 2027?”
The answer depends on the medication, prescribed dose, brand, treatment duration and additional medical care required.
Prices have already changed substantially during 2026, particularly following the introduction of lower-priced semaglutide products.
As of November 2026, official prices for the entire year 2027 are not yet available. Therefore, this guide uses documented 2026 Indian prices as a reference and explains what could influence treatment costs in 2027.
If you are considering weight loss injections in Kharghar or Navi Mumbai, understanding the total treatment expense is important before committing to long-term medication.
Based on available 2026 Indian pricing, the approximate medicine costs are:
| Weight loss injection | Reference monthly medicine cost | Price reference |
|---|---|---|
| Mounjaro (tirzepatide) | ₹13,125–₹25,781 | 2026 KwikPen listings |
| Wegovy (semaglutide) | ₹5,660–₹16,400 | 2026 dose-specific prices |
| Selected generic semaglutide products | Starting around ₹1,800 | 2026 manufacturer launch price |
These are 2026 reference prices, not confirmed 2027 prices. The generic semaglutide starting price does not represent every strength, brand or indication.
The total expense may also include consultations, investigations, nutrition support and follow-up appointments.
The most important consideration is that the starting injection price is not necessarily the amount you will pay throughout treatment.
Weight loss injections are prescription medicines that influence biological pathways involved in appetite regulation, food intake and metabolic health.
Two important medicine groups include:
GLP-1 receptor agonists act on receptors involved in appetite regulation, glucose control and gastric emptying.
Semaglutide is an example.
Tirzepatide acts on both GIP and GLP-1 receptors.
These medicines may help eligible patients reduce food intake and achieve clinically meaningful weight loss when combined with appropriate nutrition, physical activity and medical supervision.
They are not intended as unsupervised cosmetic weight-loss products.
Mounjaro contains tirzepatide, a once-weekly prescription injection.
In India, Mounjaro is available in different strengths and presentations, including single-dose vials and multidose KwikPens.
The price depends on the prescribed dose and packaging.
The following are reference prices reported by Indian pharmacy listings in 2026.
| Mounjaro dose | Approximate price for four weekly doses |
|---|---|
| 2.5 mg | ₹13,125 |
| 5 mg | ₹16,406 |
| 7.5 mg | ₹20,625 |
| 10 mg | ₹20,625 |
| 12.5 mg | ₹25,781 |
| 15 mg | ₹25,781 |
Each listed KwikPen contains four once-weekly doses.
Actual 2027 prices may differ because of manufacturer revisions, pharmacy pricing and other market changes.
Treatment generally begins at a lower dose to assess tolerability.
The prescribing doctor may gradually increase the dose according to the approved schedule, response and side effects.
Higher-strength presentations may cost more.
However, patients should not assume that the highest dose is necessary or appropriate for everyone.
The correct dose is a medical decision, not a financial or weight-loss target chosen independently.
Wegovy contains semaglutide and is used for chronic weight management in eligible patients.
It is administered once weekly.
The medicine is available in different dose strengths, and the cost changes as treatment progresses.
The following are approximate Indian reference prices reported during 2026.
| Wegovy dose | Approximate four-dose pen price |
|---|---|
| 0.25 mg | ₹5,660 |
| 0.5 mg | ₹8,100 |
| 1 mg | ₹9,100 |
| 1.7 mg | ₹12,750 |
| 2.4 mg | ₹16,400 |
These figures are useful for understanding the potential treatment budget, but they are not a guarantee of 2027 pricing.
No.
The starting dose is generally used during treatment initiation.
As the prescribed dose increases, the medicine cost may change.
Patients should therefore ask about the expected cost of the full dose-escalation period and ongoing maintenance treatment rather than focusing only on the first month.
The Indian semaglutide market changed significantly during 2026 following patent-related developments and the introduction of additional products.
Some Indian manufacturers launched lower-priced semaglutide injections.
For example, Alkem Laboratories announced a semaglutide product starting at approximately ₹1,800 for four weekly doses in March 2026.
However, this does not mean that every generic semaglutide product costs ₹1,800 per month.
Prices depend on:
Brand.
Dose strength.
Injection device.
Pack size.
Approved indication.
Pharmacy.
Product availability.
Generic semaglutide products contain the same active molecule, but they may differ in approved indications, delivery devices, strengths and product-specific instructions.
A product approved for type 2 diabetes should not automatically be treated as an interchangeable obesity-management prescription.
Your doctor must verify the specific product's approval, suitability and dosing instructions.
| Factor | Mounjaro | Wegovy | Generic semaglutide |
|---|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide | Semaglutide |
| Main pathway | Dual GIP/GLP-1 | GLP-1 | GLP-1 |
| Usual administration | Weekly | Weekly | Product-specific |
| Reference entry cost | Around ₹13,125 per four-dose KwikPen | Around ₹5,660 per four-dose pen | Selected products from around ₹1,800 |
| Cost at higher doses | Generally increases | Generally increases | Varies by product |
| Prescription required | Yes | Yes | Yes |
| Suitable for everyone? | No | No | No |
A lower medicine price does not automatically mean that a product is the most suitable option.
Treatment selection should consider approved use, medical history, expected benefits, side effects, patient preferences and affordability.
The first three months often involve dose escalation.
Therefore, calculating the cost by multiplying the starting price by three can underestimate the actual expense.
Using the listed 2026 KwikPen reference prices, an illustrative sequence could be:
| Treatment period | Example prescribed strength | Medicine cost |
|---|---|---|
| First four weeks | 2.5 mg | ₹13,125 |
| Next four weeks | 5 mg | ₹16,406 |
| Following four weeks | 7.5 mg | ₹20,625 |
| Total for 12 weeks | ₹50,156 |
This is a mathematical example, not an individualized prescription. Some patients remain at a dose longer or follow a different clinically appropriate plan.
Using the 2026 reference prices and a standard initial escalation sequence:
| Treatment period | Example prescribed strength | Medicine cost |
|---|---|---|
| First four weeks | 0.25 mg | ₹5,660 |
| Next four weeks | 0.5 mg | ₹8,100 |
| Following four weeks | 1 mg | ₹9,100 |
| Total for 12 weeks | ₹22,860 |
These calculations exclude consultation fees, laboratory investigations and other treatment expenses.
They are also based on twelve weeks, not three complete calendar months.
Annual expenses depend on the medication, dose-escalation schedule and maintenance dose.
For example, remaining on a medicine costing ₹16,400 per four-dose pen for thirteen four-week treatment periods would produce an annual medicine expense of approximately ₹2,13,200.
However, this calculation assumes a constant dose and price throughout the year.
Actual treatment may involve different doses, temporary interruptions, medication changes or discontinuation.
A personalized annual estimate should therefore be prepared using the prescribed treatment plan.
Several factors influence the cost of prescription weight-management injections.
These medicines require specialized pharmaceutical manufacturing, quality control and delivery systems.
An original branded medicine may be priced differently from another approved product containing the same active molecule.
Higher-dose presentations may cost more.
Single-dose vials, multidose pens and other approved delivery systems may have different costs.
Obesity is a chronic condition, and some patients may require medication for an extended period.
Safe treatment involves periodic assessment of response, side effects, nutritional status and metabolic health.
The complete treatment budget should include these elements rather than only the pharmacy bill.
Prices could change during 2027, but the direction and size of any future revision cannot be predicted reliably.
Several developments may influence affordability.
The availability of additional approved products may increase competition.
Lower-priced semaglutide products introduced in 2026 may continue to affect market pricing.
Companies may revise prices in response to commercial or regulatory developments.
Additional formulations or delivery systems could change available treatment choices.
The amount paid by a patient may differ from the listed maximum retail price.
There is no reliable basis to promise that Mounjaro, Wegovy or every weight loss injection will become cheaper in 2027.
Price alone does not determine safety.
A lower-priced injection may be an appropriate option when it is approved, correctly manufactured, properly stored and prescribed for the patient's condition.
However, patients should avoid purchasing products from unverified sellers.
Important precautions include:
Obtain a valid prescription.
Purchase from a licensed pharmacy.
Verify the medicine name and strength.
Check the expiry date and packaging.
Follow the manufacturer's storage instructions.
Avoid unapproved or counterfeit products.
Never substitute one medicine for another without medical advice.
A suspiciously low online price should prompt additional verification.
Eligibility depends on the specific medicine's approved indication and the patient's medical condition.
Prescription weight-management medicines may be considered for adults with obesity or overweight accompanied by certain weight-related health problems, according to the product's approved criteria.
The assessment may include:
Body mass index.
Waist circumference.
Diabetes or prediabetes.
Blood pressure.
Lipid abnormalities.
Sleep apnoea.
Previous weight-management efforts.
Current medication.
Pregnancy plans.
Other medical conditions.
BMI thresholds and eligibility criteria may differ according to the medicine's Indian prescribing information.
These injections are not appropriate for everyone who wants to lose a few kilograms.
The medicine itself is only one part of a medically supervised programme.
| Expense | Why it may be needed |
|---|---|
| Initial consultation | Assess eligibility and treatment options |
| Blood investigations | Evaluate relevant metabolic or medical conditions |
| Follow-up appointments | Review response, side effects and dosing |
| Nutrition consultation | Support adequate protein intake and sustainable eating |
| Physical activity guidance | Help preserve muscle and improve fitness |
| Additional investigations | Address symptoms or complications when indicated |
| Maintenance planning | Support long-term weight management |
Not every patient requires every service.
The actual expenses depend on the clinic, the patient's medical needs and the treatment plan.
Insurance coverage varies by policy, indication and insurer.
Many policies exclude routine outpatient obesity-management medication, but coverage should never be assumed to be universally available or universally excluded.
Patients should check:
Whether outpatient prescription medicines are covered.
Whether obesity treatment is excluded.
Whether the medicine's approved indication affects eligibility.
Whether prior authorization is required.
Whether reimbursement limits apply.
Whether associated consultations or investigations are covered.
Obtain written confirmation from your insurer before relying on reimbursement.
Cost-effectiveness is different from the purchase price.
A medicine may cost more per month but produce different clinical outcomes in a particular patient.
However, treatment response varies, and average trial results do not predict an individual's weight loss.
A meaningful comparison should consider:
Total treatment cost.
Clinical eligibility.
Expected health benefits.
Side effects.
Treatment adherence.
Dose requirements.
Long-term weight maintenance.
Patient preferences.
There is no single medicine that offers the best value for every patient.
Patients should not independently extend the interval between injections to reduce costs.
These medicines have specific approved dosing schedules.
Changing the schedule without medical supervision may affect treatment response and tolerability.
Similarly, patients should not:
Skip doses deliberately to save money.
Use a higher-strength pen in an unapproved manner.
Share injection devices.
Change the prescribed dose independently.
Restart a previously discontinued high dose without advice.
If treatment becomes unaffordable, discuss approved alternatives or a revised treatment plan with your prescribing doctor.
Not necessarily forever, but treatment should not automatically stop once a target weight is reached.
Obesity is a chronic, relapsing condition.
Some patients benefit from long-term medication, while others may need dose adjustments, a change in treatment or a medically supervised discontinuation plan.
Weight regain is common after stopping GLP-1-based treatment.
Therefore, long-term affordability is an important consideration before starting weight loss injections.
The initial monthly price should be discussed alongside the potential expense of maintenance treatment.
Common side effects of semaglutide- and tirzepatide-based treatments include:
Nausea.
Vomiting.
Diarrhoea.
Constipation.
Abdominal discomfort.
Reduced appetite.
Reflux or indigestion.
More serious problems may include pancreatitis, gallbladder disease, dehydration-related kidney injury and severe gastrointestinal reactions.
Some products have additional contraindications and warnings, including relevant personal or family histories of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
Pregnancy, pregnancy planning and other medications also require specific review.
Persistent severe abdominal pain, repeated vomiting or signs of dehydration require prompt medical attention.
Treatment suitability and safety precautions should be checked against the exact medicine's approved prescribing information.
Before beginning treatment, ask your doctor to explain the expected financial commitment.
Determine whether a prescription injection is clinically appropriate.
Review suitable medicines rather than selecting a product based only on price.
Ask how the expected medicine expense may change over the first several months.
Include consultations, investigations and nutrition support when appropriate.
Understand that treatment may continue after initial weight loss.
If costs become difficult to manage, discuss the problem before independently changing treatment.
A sustainable plan is more useful than starting a medication that cannot be continued or reviewed appropriately.
Patients considering weight loss injections in Kharghar or Navi Mumbai should undergo a medical assessment before choosing a medicine.
The consultation may cover:
Whether prescription weight-management treatment is appropriate.
Available medication options.
Expected medicine costs.
Dose escalation and monitoring.
Potential side effects.
Nutrition and protein intake.
Muscle preservation.
Physical activity.
Long-term treatment planning.
Weight maintenance.
Dr. Gunjan Gangaraju provides medical weight-management consultations in Kharghar, Navi Mumbai.
Patients can discuss treatment suitability, affordability and a personalized long-term plan before starting prescription medication.
Confirmed 2027 prices are not yet available as of November 2026. Based on 2026 reference prices, Mounjaro KwikPens cost approximately ₹13,125–₹25,781 per four weekly doses, while Wegovy costs approximately ₹5,660–₹16,400. Some generic semaglutide products have lower starting prices.
The final 2027 price will depend on the strength, presentation and prevailing pharmacy rates. In 2026, listed KwikPen prices ranged from approximately ₹13,125 to ₹25,781 for four doses.
The final 2027 price has not been confirmed. In 2026, Wegovy reference prices ranged from approximately ₹5,660 for the starter pen to ₹16,400 for the 2.4 mg pen.
Some approved generic semaglutide products have lower starting prices than branded alternatives. However, price, strength, approved indication and clinical suitability must all be considered.
Using an illustrative 12-week escalation sequence of 2.5 mg, 5 mg and 7.5 mg, the 2026 reference medicine cost is approximately ₹50,156. Individual treatment plans may differ.
Using an illustrative 12-week sequence of 0.25 mg, 0.5 mg and 1 mg, the 2026 reference medicine cost is approximately ₹22,860. This excludes additional medical expenses.
Yes. Several manufacturers introduced semaglutide products during 2026. Their approved uses, strengths, prices and delivery devices vary.
It is possible, but no specific price reduction can be guaranteed. Patients should check current official prices when purchasing.
Future prices will depend on manufacturer decisions, competition and other market factors. The 2026 price revisions do not guarantee further reductions.
Coverage depends on the insurance policy, indication and insurer. Patients should verify reimbursement conditions before starting treatment.
Another approved medication may be appropriate for some patients, but medicines are not automatically interchangeable. The decision requires medical assessment.
No. These medications are generally administered repeatedly, often once weekly, and some patients may require long-term treatment.
Treatment should not be stopped solely according to a fixed timeline without medical review. Stopping can lead to weight regain, and the long-term plan should be individualized.
Not necessarily. Medicine prices and professional consultation fees are usually separate unless a clinic explicitly offers an inclusive package.
Patients in Kharghar and Navi Mumbai can consult Dr. Gunjan Gangaraju for an individualized assessment of medication suitability, expected expenses and long-term weight-management planning.
The cost of weight loss injections in India in 2027 will depend on the medicine, dose, brand, product availability and treatment duration.
Mounjaro, Wegovy and generic semaglutide products have different price structures, and the cost of treatment may increase as the prescribed dose changes.
While the introduction of lower-priced semaglutide products has improved treatment options in India, future prices cannot be guaranteed.
Patients should consider more than the first month's injection cost.
The most useful financial question is: “Can I afford an appropriate, medically supervised treatment plan over the period I may need it?”
If you are considering prescription weight-management treatment, consult Dr. Gunjan Gangaraju in Kharghar, Navi Mumbai, to discuss your medical eligibility, available options, treatment expenses and long-term weight-management strategy.
Medical disclaimer: This article is for educational purposes. Prices are historical reference figures and are not guaranteed for 2027. Do not start, stop, substitute or change the dose of prescription weight-loss medication without advice from a qualified prescribing healthcare professional.